Brief: Tenaya Therapeutics Announces FDA Clearance Of Investigational New Drug Application
06/09/2022 13:27
Sept 6 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION AND INITIATION OF PHASE 1 SAFETY STUDY FOR
TN-301, AN HDAC6 INHIBITOR FOR HEART FAILURE WITH PRESERVED
EJECTION FRACTION
* TENAYA THERAPEUTICS INC - INITIATED ITS FIRST-IN-HUMAN
PHASE 1
CLINICAL TRIAL OF TN-301 IN HEALTHY ADULT PARTICIPANTS
Source text for Eikon: ID:nGNX7dTlhz
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027